RAG-17 is an experimental RNA-targeting therapy designed to lower toxic SOD1 protein in people with SOD1-ALS. A six-person trial found RAG-17 was well tolerated, with no serious side effects. RAG-17 ...

Over the last five years, Canadian ALS clinics have shifted from offering genetic testing mainly to people with a family ...

A PBS documentary, "Loving John," explores a gay American Samoan man's final years with ALS. It highlights the disease's ...

Although I continue to rely on a rollator to help me walk inside the house and a mobility scooter when I’m out and about, getting the power wheelchair was a strategic, planning-ahead decision. I live ...

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

A self-balancing robotic exoskeleton was found safe and feasible for ALS patients with gait impairment. It helps patients practice walking hands-free, improving mobility, posture, and well-being.

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects people differently, with ALS prognosis varying considerably from one person to another. The condition gradually ...

ALS is linked to toxic TDP-43 protein clumps. A new strategy targets a specific protein region. A small molecule, XL20, prevents clumping, reducing nerve damage in human cells. XL20 extended survival ...

An expanded access program for Qalsody in ALS patients was feasible and well-tolerated. The program provided Qalsody to 11 ALS patients ineligible for trials. A mixed funding model, including ...

I walked with our dog, Comet, on a trail in the woods behind our house. The woods felt cool out of the hot sun. Light filtered through the trees overhead as I breathed in the rich smell of summer ...

Australian data links over 10% of ALS cases to known genetic mutations. The SALSA-SGC consortium collects data to understand ALS causes and progression. The project brings together seven major motor ...